No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial

• J. Alagaratnam,
• W. Stohr,
• J. Toombes,
• H. Zetterberg,
• S. Pett,
• M. Nelson,
• S. Kinloch,
• A. Clarke,
• N. Nwokolo,
• M. Johnson,
• J. Fox,
• T. Hanke,
• J. Kopycinski,
• L. Dorrell,
• A. Babiker,
• J. Frater,
• A. Winston,
• S. Fidler

Affiliations

J. Alagaratnam

Imperial College, London, UK; Imperial College Healthcare NHS Trust, London, UK

W. Stohr

University College London, MRC Clinical Trials Unit, London, UK

J. Toombes

University College London, London, UK

H. Zetterberg

University College London, London, UK; University of Gothenburg, Gothenburg, Sweden

S. Pett

University College London, MRC Clinical Trials Unit, London, UK

M. Nelson

Chelsea and Westminster Hospital, London, UK

S. Kinloch

Royal Free London NHS Foundation Trust, London, UK

A. Clarke

Brighton and Sussex University Hospital, Brighton, UK

N. Nwokolo

Chelsea and Westminster Hospital, London, UK

M. Johnson

Royal Free London NHS Foundation Trust, London, UK

J. Fox

Guy's and St Thomas’ NHS Foundation Trust, London, UK

T. Hanke

University of Oxford, Oxford, UK

J. Kopycinski

University of Oxford, Oxford, UK

L. Dorrell

University of Oxford, Oxford, UK

A. Babiker

University College London, MRC Clinical Trials Unit, London, UK

J. Frater

University of Oxford, Oxford, UK

A. Winston

Imperial College, London, UK; Imperial College Healthcare NHS Trust, London, UK

S. Fidler

Imperial College, London, UK; Imperial College Healthcare NHS Trust, London, UK